Impact thérapeutique des bactériémies à streptocoques et à entérocoques chez des malades d'hématologie

1990, Gram-positive bacteraemia in granulocytopenic patients, Eur J Cancer, 26, 569, 10.1016/0277-5379(90)90079-9 Cometta, 1995, Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer, Antimicrob Agents Chemother, 39, 445, 10.1128/AAC.39.2.445 Oppenheim, 1998, The changing pattern of infection in neutropenic patients, J Antimicrob Chemother, 41, 7, 10.1093/jac/41.suppl_4.7 Schlegel, 2000, Streptococcaceae : Streptococcus, Abiotrophia, Enterococcus, Lactococcus, Aerococcus et autres genres apparentés, 835 Bouvet, 1994, Identification des entérocoques en microbiologie clinique, Méd Mal Infect, 24, 132, 10.1016/S0399-077X(05)80296-3 1999, Communiqué 1999, Patho Biol, 47, 845 1979 Pizzo, 1993, Management of fever in patients with cancer and treatment-induced neutropenia, N Engl J Med, 328, 1323, 10.1056/NEJM199305063281808 Bouvet, 1997, Infections invasives à streptocoques viridans (streptocoques oraux) en dehors des pneumococcies, Presse Méd, 26, 1768 Herbrecht, 1994, Les infections à cocci à Gram positif en hématologie et en cancérologie, Méd Mal Infect, 24, 1222, 10.1016/S0399-077X(05)81041-8 Cometta A, Cordonnier C, Quentin C, et al. Infection à Gram positif chez le patient neutropénique. Lettre du cancérologue. 1997 ; Suppl (Info Sympo) : 1-7 Wisplinghoff, 1999, Molecular relationships and antimicrobal susceptibilities of viridans group Streptococci isolated from blood of neutropenic cancer patients, J Clin Microbiol, 37, 1876, 10.1128/JCM.37.6.1876-1880.1999 Awada, 1992, Streptococcal and enterococcal bacteremia in patients with cancer, Clin Infect Dis, 15, 33, 10.1093/clinids/15.1.33 1991, Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients, J Infect Dis, 163, 951, 10.1093/infdis/163.5.951 Pizzo, 1978, Increasing incidence of Gram positive sepsis in cancer patients, Med Pediatr Oncol, 5, 241, 10.1002/mpo.2950050133 Shenep, 2000, Viridans-group streptococcal infections in immunocompromised hosts, Int J Antimicrob Agents, 14, 129, 10.1016/S0924-8579(99)00172-7 Jagarlamudi, 2000, Infections in acute leukemia: an analysis of 240 febrile episodes, Med Oncol, 17, 111, 10.1007/BF02796205 Weisman, 1990, Septicemia in pediatric oncology patients: the significance of viridans streptococcal infections, J Clin Oncol, 8, 453, 10.1200/JCO.1990.8.3.453 Rosser, 1999, E test versus agar dilution for antimicrobial susceptibilty testing of viridans group streptococci, J Clin Microbiol, 37, 26, 10.1128/JCM.37.1.26-30.1999 Berner, 1998, Bacteremic episodes in pediatric oncologic patients, especially caused by the streptococcus viridans group, Klin Pediat, 210, 256, 10.1055/s-2008-1043888 Grob, 1991, Épidémiologie et facteurs de risque infectieux, 1 Schots, 2000, The clinical impact of early gram-positive bacteremia and the use of vancomycin after allogenic bone marrow transplantation, Transplantation, 69, 1511, 10.1097/00007890-200004150-00053 Allouch P, Estenne B, Kwantes M, Ghnassia JC. Bactériologie des infections mixtes. Méd Mal Infect 1986 ; Spécial : 4-11 Donald, 1985, Bacterial synergism between the Enterococcus and Escherichia coli, J Surg Res, 38, 475, 10.1016/0022-4804(85)90064-2 Schmit JL, Leclercq R, Scheimberg A, Landauer D. Approche épidémiologique et clinique des entérocoques : résultats d'une enquête. Méd Mal Infect 1994 ; Spécial : 141-8 Leblanc, 1989, Fréquence et gravité des infections systémiques à streptocoques mitis et sanguis II chez les enfants neutropéniques, Path Biol, 37, 459 Varon E, Braye A, Rybkine T, Devine C, Bouvet A. Emergence of oral streptococci with moderate susceptibility or resistance to penicillin G in clinical specimens (abstract 21/C3). 15éme Réunion interdisciplinaire de Chimiothérapie Anti-Infectieuse, Paris, 7–8 décembre 1995 Doern, 1996, Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States, Antimicrob Agents Chemother, 40, 891, 10.1128/AAC.40.4.891 Alcaide, 1995, In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood, Antimicrob Agents Chemother, 39, 2243, 10.1128/AAC.39.10.2243 Kern, 1999, Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy, N Engl J Med, 341, 312, 10.1056/NEJM199907293410502 Marie, 1995, Association pipéracilline-tazobactam+amikacine versus ceftazidime+amikacine chez les patients neutropéniques. Étude multicentrique ouverte, Presse Méd, 24, 397 Hugues, 1997, Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Unexplained Fever, Clin Infect Dis, 25, 551, 10.1086/513764 Le Guyader, 2000, Antibactériens et épisodes de neutropénie fébrile, Dossier du Centre national hospitalier d'information sur le médicament, XXI, 8 Marie, 1999, Piperacilline-tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients, Support Care Cancer, 7, 89, 10.1007/s005200050233 Reiffers J, Cony-Makhoul P, et al. Efficacy of Cefpirome in the initial empirical management of febrile neutropenic patients with hematological malignancies. 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy 1992, Anaheim, Californie Sanders, 1991, Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis, J Infect Dis, 164, 907, 10.1093/infdis/164.5.907 Freifeld, 1995, Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipeneme, J Clin Oncol, 13, 165, 10.1200/JCO.1995.13.1.165 Marron, 2000, Serious complications of bacteremia caused by viridans streptococci in neutropenic patients with cancer, Clin Infect Dis, 31, 1126, 10.1086/317460